Cargando…
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici O...
Autores principales: | Campo, Flaminia, Venuti, Aldo, Pimpinelli, Fulvia, Abril, Elva, Blandino, Giovanni, Conti, Laura, De Virgilio, Armando, De Marco, Federico, Di Noia, Vincenzo, Di Domenico, Enea Gino, Di Martino, Simona, Ensoli, Fabrizio, Giannarelli, Diana, Mandoj, Chiara, Mazzola, Francesco, Moretto, Silvia, Petruzzi, Gerardo, Petrone, Fabrizio, Pichi, Barbara, Pontone, Martina, Vidiri, Antonello, Vujovic, Branka, Piaggio, Giulia, Sperandio, Eleonora, Rosati, Valentina, Cognetti, Francesco, Morrone, Aldo, Ciliberto, Gennaro, Pellini, Raul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538824/ https://www.ncbi.nlm.nih.gov/pubmed/34696233 http://dx.doi.org/10.3390/vaccines9101125 |
Ejemplares similares
-
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
por: Pellini, Raul, et al.
Publicado: (2021) -
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine
por: Pellini, Raul, et al.
Publicado: (2021) -
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
por: Pimpinelli, Fulvia, et al.
Publicado: (2021) -
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
por: Pimpinelli, Fulvia, et al.
Publicado: (2021) -
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas
por: Marchesi, Francesco, et al.
Publicado: (2021)